Novartis AG (ADR) (NVS): Why Incyte Corporation (INCY) Shares Skyrocketed

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company focused on developing therapies to treat oncology and inflammation-based diseases, skyrocketed as much as 32% after reporting top-line data from a proof-of-concept trial involving ruxolitinib for refractory metastatic pancreatic cancer.

Incyte Corporation (NASDAQ:INCY)

So what: In its phase 2a trial, Incyte Corporation (NASDAQ:INCY) notes that ruxolitinib — its oral JAK1 and JAK2 inhibitor that’s currently approved to treat myelofibrosis under the trade name Jakafi — when combined with Roche‘s Xeloda demonstrated a hazard ratio for overall survival in the intent to treat population of 0.79. In a pre-specified subgroup that was expected to benefit most from JAK pathway inhibition, the hazard ratio for overall survival was 0.47, with six-months survival at 42% for the ruxolitinib arm compared to just 11% for the placebo. Also, only patients in the ruxolitinib arm showed durable tumor response and significant improvement in body weight.

Now what: As you can tell by today’s move higher, this is incredibly good early stage news for advanced metastatic pancreatic sufferers. Furthermore, it appears that Incyte Corporation (NASDAQ:INCY) has already honed in on which subgroups would benefit most by JAK pathway inhibition, meaning that a companion diagnostic test may be unnecessary. Jakafi delivered improved overall survivial in a phase 3 myelofibrosis trial, which lends hope that ruxolitinib to treat metastatic prostate cancer will do the same. With regard to Incyte Corporation (NASDAQ:INCY), I’d love to see a pullback from today’s pop but would certainly understand if it didn’t.

Not to be forgotten in this as well is Novartis AG (ADR) (NYSE:NVS), which has full licensing rights to ruxolitinib outside the United States. If things continue to go well for ruxolitinib it’ll mean less lost sleep at night for Novartis AG (ADR) (NYSE:NVS) shareholders who are looking for new therapies to take the reins as patent expirations sweep through the pharmaceutical industry.

The article Why Incyte Shares Skyrocketed originally appeared on Fool.com and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!